GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells

@article{Shi2010GDP366AN,
  title={GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells},
  author={Xianping Shi and Deping Wang and Ke Ding and Zhongzheng Lu and Yanli Jin and Jin Zhang and Jingxuan Pan},
  journal={Cancer Biology \& Therapy},
  year={2010},
  volume={9},
  pages={640 - 650}
}
Accumulating evidence indicates that survivin plays a pivotal role in not only cell survival but also cell cycle progression. Op18/stathmin is an oncoprotein that regulates microtubule stabilization. Both survivin and Op18 have been proposed as therapeutic targets for cancer. However, few small molecule inhibitors of survivin and Op18 have been reported. In this study, we have identified a novel small molecule compound (GDP366) which potently and selectively inhibited the expression of both… 
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis
TLDR
Results indicated that GDP366 and AD80 reduced the PI3K/STMN1 axis and had cytotoxic effects in acute leukemia cellular models, which highlight STMN1-mediated signaling as a putative anticancer target for acute leukemia.
Trace of survivin in cancer
TLDR
Multiple molecular approaches such as use of the RNA interfering technique, antisense oligonucleotides, ribozyme, and small molecule inhibitors have been used to downregulate survivin regulation and inhibit its biological function consequently.
A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells
TLDR
It is found that siRNA-mediated silencing of Stathmin suppresses proliferation, induces apoptosis through the mitochondrial pathway, and causes G2/M-phase cell cycle arrest in the NPC cell lines CNE1-LMP1 and HNE2.
Survivin: a unique target for tumor therapy
TLDR
Overall, Survivin emerges as a molecule with much wider role in cellular homeostasis and its role in regulation of apoptosis, cell division, chemo-resistance and tumour progression is discussed.
Therapeutic strategies involving survivin inhibition in cancer
TLDR
In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed and the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated.
Discovery of survivin inhibitors and beyond: FL118 as a proof of concept.
  • Fengzhi Li
  • Biology
    International review of cell and molecular biology
  • 2013
Therapeutic strategies involving survivin inhibition in cancer Running title: Survivin inhibition in cancer therapy
TLDR
In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed and the major signalling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated.
Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics
TLDR
The expression of survivin in normal and cancer cells is analyzed with a particular focus on its expression in cancer stem cell compartment and the challenges involving the development of potent and specific survivin inhibitors for cancer therapeutics are discussed.
Survivin and gynaecological tumours.
...
1
2
3
...

References

SHOWING 1-10 OF 35 REFERENCES
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
TLDR
These findings represent the first attempt to show tumor regression and suppression of survivin in p53-deficient human HRPC cells by a single small molecular compound treatment.
SPC3042: a proapoptotic survivin inhibitor
TLDR
A new potent antisense inhibitor of survivin is presented, and the properties of SPC3042 are compared with the previously published antisense drug, LY2181308/ISIS23722.
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers
TLDR
Over-expression of survivin counteracts the therapeutic effect of microtubule de-stabilizer BPR0L075 probably by stabilizing tubulin polymers, instead of the inhibition of caspase activity in cancer cells.
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
TLDR
The multiple functions of Survivin in the regulation of apoptosis, the promotion of tumorigenesis, and the development of survivin inhibitors as a novel anticancer therapeutic strategy are reviewed.
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
TLDR
Results unambiguously establish p21 as a critical mediator of one well-documented p53 function and have important implications for understanding cell cycle checkpoints and the mechanism(s) through which p53 inhibits human neoplasia.
Stathmin 1: a novel therapeutic target for anticancer activity
TLDR
Available data is summarized as rationale for the therapeutic manipulation of STMN1 in cancer patients and its expression is also upregulated in hepatocytes during regeneration and in lymphoid cells when they are signaled to proliferate.
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
TLDR
It is shown that control of apoptosis and preservation of p21 integrity within centrosomes by survivin are required for normal mitotic progression.
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells.
TLDR
The senescent phenotype distinguishes tumor cells that survived drug exposure but lost the ability to form colonies from those that recover and proliferate after treatment, and should assist in improving the efficacy and decreasing side effects of cancer therapy.
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
TLDR
The data suggest that survivin is regulated by the Bcr-Abl/MAPK cascade in Ph+ CML and the potential therapeutic utility of this strategy in patients with CML, both imatinib sensitive and resistant is suggested.
Oncoprotein 18 is a phosphorylation‐responsive regulator of microtubule dynamics.
TLDR
MTs in cells induced to express either wild‐type or mutated Op18 are analyzed and it is concluded that Op18 decreases MT stability and that this activity of Op18 is subject to cell cycle regulation by CDKs.
...
1
2
3
4
...